유럽 연합 - 영어 - EMA (European Medicines Agency)

astellas pharma europe b.v. - micafungin - candidiasis - antimycotics for systemic use - mycamine is indicated for:adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.the decision to use mycamine should take into account a potential risk for the development of liver tumours. mycamine should therefore only be used if other antifungals are not appropriate.

미국 - 영어 - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. - kalmia latifolia leaf (unii: 79n6542n18) (kalmia latifolia leaf - unii:79n6542n18) - kalmia latifolia leaf 3 [hp_x]

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 33 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 99 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hyprolose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 33 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 99 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; hyprolose; crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 66 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 66 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

이스라엘 - 영어 - Ministry of Health

cts ltd - patiromer as sorbitex calcium - powder for suspension - patiromer as sorbitex calcium 16.8 g - patiromer calcium - veltassa is indicated for the treatment of hyperkalaemia in adults

이스라엘 - 영어 - Ministry of Health

cts ltd - patiromer as sorbitex calcium - powder for suspension - patiromer as sorbitex calcium 16.8 g - patiromer calcium - veltassa is indicated for the treatment of hyperkalaemia in adults